Sarah Anne Whelan

Title: Sarah Anne Whelan: Innovator in Cell-Based Immunotherapy

Introduction

Sarah Anne Whelan is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of immunotherapy, particularly through her innovative work on CBL inhibitors. Her research focuses on enhancing the efficacy of cell-based immunotherapeutics, which has the potential to revolutionize treatment options for various diseases.

Latest Patents

Whelan holds a patent for "CBL inhibitors and compositions for use in adoptive cell therapy." This patent discloses methods and compositions that utilize novel CBL inhibitors to support the engraftment of immune cells. The goal is to increase the effectiveness of cell-based immunotherapeutics. Additionally, her work includes cell-based immunotherapy methods and compositions that leverage these novel CBL inhibitors for the propagation of cells desirable for use in such therapies. She has 1 patent to her name.

Career Highlights

Whelan is currently employed at Nurix Therapeutics, Inc., where she continues to advance her research in immunotherapy. Her work is pivotal in developing new therapeutic strategies that harness the power of the immune system to fight diseases.

Collaborations

Some of her notable coworkers include Jennifa Gosling and Arthur T. Sands. Their collaborative efforts contribute to the innovative environment at Nurix Therapeutics, Inc.

Conclusion

Sarah Anne Whelan is a trailblazer in the field of cell-based immunotherapy, with her groundbreaking patent and ongoing research at Nurix Therapeutics, Inc. Her contributions are paving the way for more effective treatments in the future.